Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases
NCT07274709 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2495
Last updated 2026-05-12
Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Initiation of ribociclib
Initiation of ribociclib plus letrozole described in electronic health records is used as the exposure
- DRUG
-
Initiation of letrozole
Initiation of letrozole described in electronic health records is used as the reference
Sponsors & Collaborators
-
Food and Drug Administration (FDA)
collaborator FED -
Shirley Vichy Wang
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
-
Denys Shay, MD · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-07
- Primary Completion
- 2026-01-01
- Completion
- 2026-01-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
NCT02562118 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
NCT01576666 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase IIa Study to Evaluate NBQ72S
NCT06810804 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
NCT02857270 ·Status: COMPLETED ·Phase: PHASE1
-
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
NCT04460898 ·Status: COMPLETED
-
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
NCT01341457 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
NCT05296746 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of E7389 for Advanced or Metastatic Breast Cancer
NCT00965523 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
NCT05286437 ·Status: RECRUITING ·Phase: PHASE2
-
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
NCT01872260 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891 ·Status: RECRUITING ·Phase: PHASE2
-
Computation Prediction of Drug Response Based on Omics Data
NCT05833802 ·Status: UNKNOWN
-
A Study of LY3023414 in Participants With Advanced Cancer
NCT01655225 ·Status: COMPLETED ·Phase: PHASE1
-
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
NCT01857193 ·Status: COMPLETED ·Phase: PHASE1
-
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
NCT02313051 ·Status: UNKNOWN ·Phase: PHASE2
-
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
NCT05190094 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
NCT01240421 ·Status: APPROVED_FOR_MARKETING
-
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
NCT06656624 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
NCT02058381 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Finding Study of E7070 in Combination With Irinotecan
NCT00060567 ·Status: COMPLETED ·Phase: PHASE1
-
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
NCT01740427 ·Status: COMPLETED ·Phase: PHASE3